Compound class:
Synthetic organic
Comment: The structure for davelizomib was obtained from proposed INN list 129 (August 2023) where it is described as a proteasome inhibitor and antineoplastic agent. It is example I-1 in patent JP2021531302A. This patent encompasses use of claimed compounds for the treatment of multiple myeloma, and identifies its potential in MM that is resistant to treatment with the existing proteasome inhibitor bortezomib.
|
|
Download 2D Structure | |
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel